Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00162266




Registration number
NCT00162266
Ethics application status
Date submitted
9/09/2005
Date registered
13/09/2005
Date last updated
1/06/2012

Titles & IDs
Public title
Abatacept With Methotrexate- Phase IIB
Scientific title
A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Two Different Doses of BMS-188667 Administered Intravenously to Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate
Secondary ID [1] 0 0
IM101-100
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Abatacept (BMS-188667)
Treatment: Drugs - Abatacept (BMS-188667)
Treatment: Drugs - Abatacept (BMS-188667)
Treatment: Drugs - Placebo

Experimental: Abatacept (10 mg/Kg) - Open Label -

Experimental: Abatacept (2 mg/kg) - Double blind -

Experimental: Abatacept (10 mg/kg) - Double blind -

Experimental: Placebo - Double blind -


Treatment: Drugs: Abatacept (BMS-188667)
IV, 10 mg/Kg, monthly, for the duration of the trial

Treatment: Drugs: Abatacept (BMS-188667)
Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months

Treatment: Drugs: Abatacept (BMS-188667)
Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months

Treatment: Drugs: Placebo
Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Responders to American College of Rheumatology 20% Improvement Criteria (ACR 20) at Day 180 of the Double-Blind (DB) Period
Timepoint [1] 0 0
Day 180
Primary outcome [2] 0 0
Participants Receiving Concomitant Disease Modifying Rheumatic Drugs and Biologics in Open-Label (OL) Period
Timepoint [2] 0 0
Day 360 to Day 3,060
Primary outcome [3] 0 0
Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) in OL Period
Timepoint [3] 0 0
Day 360 to Day 3060
Primary outcome [4] 0 0
Number of Participants With AEs of Special Interest in OL Period
Timepoint [4] 0 0
Day 360 to Day 3060
Primary outcome [5] 0 0
Baseline Serum Immunoglobulin A (IgA) Over Time in OL Period
Timepoint [5] 0 0
Baseline (Day 0) and Days 360, 720,1080, 1440, and 1800
Primary outcome [6] 0 0
Mean Change From Baseline (BL) in IgA Over Time in OL Period
Timepoint [6] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800
Primary outcome [7] 0 0
Baseline Immunoglobulin G (IgG) Over Time in OL Period
Timepoint [7] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440 and 1800
Primary outcome [8] 0 0
Mean Change From Baseline (BL) in IgG Over Time in OL Period
Timepoint [8] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800
Primary outcome [9] 0 0
Baseline Immunoglobulin M (IgM) Over Time in OL Period
Timepoint [9] 0 0
Baseline (Day 0) and Days 360, 720,1080,1440, and 1800
Primary outcome [10] 0 0
Mean Change From Baseline (BL) in IgM in OL Period
Timepoint [10] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800
Primary outcome [11] 0 0
Number of Participants With Hematology Values Meeting Marked Abnormality Criteria in OL Period
Timepoint [11] 0 0
Day 360 to Day 3060
Primary outcome [12] 0 0
Number of Participants With Liver and Kidney Function Values Meeting Marked Abnormality Criteria in OL Period
Timepoint [12] 0 0
Day 360 to Day 3060
Primary outcome [13] 0 0
Number of Participants With Electrolyte Values Meeting Marked Abnormality Criteria in OL Period
Timepoint [13] 0 0
Day 360 to Day 3060
Primary outcome [14] 0 0
Number of Participants With Glucose, Protein, Metabolites, and Urinalysis Values Meeting Marked Abnormality Criteria in OL Period
Timepoint [14] 0 0
Day 360 to Day 3060
Secondary outcome [1] 0 0
Number of ACR 20 Responders in DB Period
Timepoint [1] 0 0
Days 15, 30, 60, 90, 120, 150,180, 240, 300, and 360
Secondary outcome [2] 0 0
Number of ACR 50 Responders in DB Period
Timepoint [2] 0 0
Day 15; Day 30; Day 60; Day 90; Day 120; Day 150; Day 180; Day 240; Day 300; Day 360
Secondary outcome [3] 0 0
Number of ACR 70 Responders in DB Period
Timepoint [3] 0 0
Day 15; Day 30; Day 60; Day 90; Day 120; Day 150; Day 180; Day 240; Day 300; Day 360
Secondary outcome [4] 0 0
ACR Numeric Values (ACR-N)
Timepoint [4] 0 0
Day 15; Day 30; Day 60; Day 90; Day 120; Day 150; Day 180; Day 240; Day 300; Day 360
Secondary outcome [5] 0 0
ACR-N Area Under The Curve (AUC) on Day 180 and Day 360
Timepoint [5] 0 0
Baseline and Day 180; Baseline and Day 360
Secondary outcome [6] 0 0
Individual Components of ACR Criteria--Mean Percentage Change From Baseline at Day 180
Timepoint [6] 0 0
Baseline, Day 180
Secondary outcome [7] 0 0
Individual Components of ACR Criteria--Mean Percentage Change From Baseline at Day 360
Timepoint [7] 0 0
Baseline, Day 360
Secondary outcome [8] 0 0
Mean Changes From Baseline in the Short Form 36 (SF-36) Physical and Mental Health Component Summary Scores (PCS and MCS) at Day 180 and Day 360
Timepoint [8] 0 0
Baseline, Day 180, Day 360
Secondary outcome [9] 0 0
Adjusted Mean Percent Changes From Baseline in the Modified Health Assessment Questionnaire (mHAQ) at Day 180 and Day 360
Timepoint [9] 0 0
Baseline, Day 180, Day 360
Secondary outcome [10] 0 0
Number of Participants With At Least One New Active Joint (Tender Joints and Swollen Joints) at Day 180 and Day 360
Timepoint [10] 0 0
Day 180, Day 360
Secondary outcome [11] 0 0
Participants Who Experienced Death, Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations During the Double-Blind Period
Timepoint [11] 0 0
From the start of study through the end of the double-blind period (at 12 months)
Secondary outcome [12] 0 0
Participants With Laboratory Abnormalities Meeting the Marked Abnormality Criteria for Selected Blood Chemistry Values During Double-Blind Therapy
Timepoint [12] 0 0
From the start of study up to 60 days post the end of the 12-month double-blind period
Secondary outcome [13] 0 0
Participants With Laboratory Abnormalities Meeting the Marked Abnormality Criteria for Selected Hematologic Values During Double-Blind Therapy
Timepoint [13] 0 0
From the start of study up to 60 days post the end of the 12-month double-blind period
Secondary outcome [14] 0 0
Number of Participants Who Discontinued Due to Lack of Efficacy in the DB and OL Periods
Timepoint [14] 0 0
Day 1 to Day 360 (Double-Blind Period), Day 361 to Day 3060 (Open-Label Period)
Secondary outcome [15] 0 0
Immunogenicity Data: Anti-CTLA4Ig Antibodies With Immunoglobulin (IG) Region
Timepoint [15] 0 0
Baseline, Days 30, 90, 180, 270, 360
Secondary outcome [16] 0 0
Immunogenicity Data: Anti-CTLA4Ig Antibodies Without IG Region
Timepoint [16] 0 0
Baseline, Days 30, 90, 180, 270, 360
Secondary outcome [17] 0 0
Immunogenicity Data: Categories of Post Baseline Value to Baseline Value (VA/PRE) Ratios and Number of Participants With Sero-conversion (Anti-CTLA4Ig Antibodies With IG Region)
Timepoint [17] 0 0
Baseline, Days 30, 90, 180, 270, 360
Secondary outcome [18] 0 0
Immunogenicity Data: Categories of Post Baseline Value to Baseline Value (VA/PRE) Ratios and Number of Participants With Sero-conversion(Anti-CTLA4Ig Antibodies Without IG Region)
Timepoint [18] 0 0
Baseline, Days 30, 90, 180, 270, 360
Secondary outcome [19] 0 0
Pharmacodynamic Measure: Mean Changes From Baseline in Rheumatoid Factor at Day 180 and Day 360
Timepoint [19] 0 0
Baseline, Day 180, Day 360
Secondary outcome [20] 0 0
Pharmacodynamic Measure: Mean Changes From Baseline in Interleukin-6 at Day 180 and Day 360
Timepoint [20] 0 0
Baseline, Day 180, Day 360
Secondary outcome [21] 0 0
Pharmacodynamic Measure: Mean Changes From Baseline in Plasma Soluble Interleukin-2 Receptor (sIL-2R) at Day 180 and Day 360
Timepoint [21] 0 0
Baseline, Day 180, Day 360
Secondary outcome [22] 0 0
Pharmacodynamic Measure: Mean Changes From Baseline in E-Selectin at Day 180 and Day 360
Timepoint [22] 0 0
Baseline, Day 180, Day 360
Secondary outcome [23] 0 0
Pharmacodynamic Measure: Mean Changes From Baseline in Soluble Inter-Cellular Adhesion Molecule 1 (sICAM-1) at Day 180 and Day 360
Timepoint [23] 0 0
Baseline, Day 180, Day 360
Secondary outcome [24] 0 0
Pharmacodynamic Measure: Mean Changes From Baseline in Tumor Necrosis Factor (TNF)-Alpha at Day 180 and Day 360
Timepoint [24] 0 0
Baseline, Day 180, Day 360
Secondary outcome [25] 0 0
Number of ACR 20 Responders in OL Period
Timepoint [25] 0 0
Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060
Secondary outcome [26] 0 0
Number of ACR 50 Responders in the OL Period
Timepoint [26] 0 0
Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060
Secondary outcome [27] 0 0
Number of ACR 70 Responders in the OL Period
Timepoint [27] 0 0
Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060
Secondary outcome [28] 0 0
Number of Participants With a Clinically Meaningful Improvement on the Modified Health Assessment Questionnaire (mHAQ) in OL Period
Timepoint [28] 0 0
Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [29] 0 0
Baseline Level of Serum Rheumatoid Factor Over Time in OL Period
Timepoint [29] 0 0
Baseline (Day 0) and Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [30] 0 0
Mean Change From Baseline in Serum Rheumatoid Factor Level Over Time in OL Period
Timepoint [30] 0 0
Baseline (Day 0) and Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [31] 0 0
Mean Baseline Soluble Serum Interleukin-2 Receptor Level (sIL2-r) Over Time in OL Period
Timepoint [31] 0 0
Baseline (Day 0) and Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [32] 0 0
Mean Change From Baseline in sIL2-r Over Time in OL Period
Timepoint [32] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800
Secondary outcome [33] 0 0
Mean Baseline Serum C-Reactive Protein Level Over Time in OL Period
Timepoint [33] 0 0
Baseline (Day 0) and Days 360, 720, 1080,1440,1800, 2160, 2520, 2880, 3060
Secondary outcome [34] 0 0
Mean Change From Baseline in Level of C Reactive Protein Over Time in OL Period
Timepoint [34] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, 3060
Secondary outcome [35] 0 0
Mean Baseline Physical Component Summary (PCS) of the Short-Form 36 (SF-36) Over Time in OL Period
Timepoint [35] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2880, and 3060
Secondary outcome [36] 0 0
Mean Change From Baseline (BL) in the Physical Component Summary (PCS) of the SF-36 Over Time in OL Period
Timepoint [36] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2880, and 3060
Secondary outcome [37] 0 0
Mean Baseline Mental Component Summary (MCS) of the SF-36 Over Time in OL Period
Timepoint [37] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2880, and 3060
Secondary outcome [38] 0 0
Mean Change From Baseline (BL) in the MCS of the SF-36 Over Time in OL Period
Timepoint [38] 0 0
Baseline (Day 0) and Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060
Secondary outcome [39] 0 0
Mean Baseline (BL) Physical Functioning Domain of the SF-36 Over Time in OL Period
Timepoint [39] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [40] 0 0
Mean Change From Baseline (BL) in the Physical Functioning Domain of the SF-36 Over Time in OL Period
Timepoint [40] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [41] 0 0
Mean Baseline Role-Physical Domain of the SF-36 Over Time in OL Period
Timepoint [41] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [42] 0 0
Mean Change From Baseline (BL) in the Role-Physical Domain of the SF-36 Over Time in OL Period
Timepoint [42] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [43] 0 0
Mean Baseline Bodily Pain Domain of the SF-36 Over Time in OL Period
Timepoint [43] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [44] 0 0
Mean Change From BL in the Bodily Pain Domain of the SF-36 Over Time in OL Period
Timepoint [44] 0 0
BL (Day 0); Day 360; Day 720; Day 1,080; Day 1,440; Day 1,800; Day 2,160; Day 2,520; Day 2,880; Day 3,060
Secondary outcome [45] 0 0
Mean BL General Health Domain of the SF-36 Over Time in OL Period
Timepoint [45] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [46] 0 0
Mean Change From Baseline (BL) in the General Health Domain of the SF-36 Over Time in OL Period
Timepoint [46] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [47] 0 0
Mean Baseline Vitality Domain of the SF-36 Over Time in OL Period
Timepoint [47] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [48] 0 0
Mean Change From Baseline (BL) in the Vitality Domain of the SF-36 Over Time in OL Period
Timepoint [48] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [49] 0 0
Mean Baseline Social Functioning Domain of the SF-36 Over Time in OL Period
Timepoint [49] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [50] 0 0
Mean Change From Baseline (BL) in the Social Functioning Domain of the SF-36 Over Time in OL Period
Timepoint [50] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [51] 0 0
Mean Baseline Role-Emotional Domain of the SF-36 Over Time in OL Period
Timepoint [51] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [52] 0 0
Mean Change From Baseline (BL) in the Role-Emotional Domain of the SF-36 Over Time in OL Period
Timepoint [52] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [53] 0 0
Mean Baseline Mental Health Domain of the SF-36 Over Time in OL Period
Timepoint [53] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Secondary outcome [54] 0 0
Mean Change From Baseline (BL) in the Mental Health Domain of the SF-36 Over Time in OL Period
Timepoint [54] 0 0
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

Eligibility
Key inclusion criteria
Double blind study phase:

1. Males or females (not nursing and not pregnant), at least 18 years of age. Women of
child bearing potential (WOCBP) are eligible if they are practicing effective
contraceptive measures

2. Subjects must meet the criteria of the American Rheumatism Association (1987) for the
diagnosis of rheumatoid arthritis and the American College of Rheumatology (1991)
functional classes I, II, or III

3. Subjects have been taking Methotrexate (10-30 mg weekly) for at least 6 months, and at
a stable dose for 28 days prior to treatment

4. Washout/drug stabilization requirements (except Methotrexate) [Informed consent must
be signed before making any changes in RA therapy if those changes are solely for the
purpose of this study].

- Leflunomide or Infliximab have already been discontinued at least 60 days prior
to enrollment (prior to signing of informed consent) and a total of 90 days prior
to treatment. All other Disease Modifying Anti-Rheumatic Drugs (DMARDs) (except
Methotrexate) have been withdrawn at least 28 days prior to treatment

- Oral corticosteroid treatment has been reduced to the equivalent of 10 mg or less
prednisone daily and stabilized for at least 28 days prior to enrollment

5. Eligibility of subjects for the study is based on their disease activity and
anti-rheumatic treatment at the initial visit:

- Methotrexate monotherapy: Subject is receiving only Methotrexate, steroids,
Non-steroidal anti-inflammatory drugs (NSAIDs) and will not require washout

- Combination therapy: Subject is receiving Methotrexate in combination with
another DMARD(s) and will require washout

At entry, Methotrexate monotherapy must have a disease activity:

- 10 or more swollen joints (66 joint count)

- 12 or more tender joints (68 joint count)

- C reactive protein (CRP) =.1 mg/dL (10 mg/L) at "Screening" visit

At entry, combination therapy must have a disease activity (if subject does not
satisfy the above):

- 6 or more swollen joints (66 joint count)

- 8 or more tender joints (68 joint count)

- No restriction on C-reactive protein (CRP)

In addition

All subjects who were on combination therapy at entry must undergo a 28 day washout
period of DMARDs other than Methotrexate. After the washout/drug stabilization and
prior to randomization such subjects must have:

- 10 or more swollen joints (66 joint count)

- 12 or more tender joints (68 joint count)

- C reactive protein (CRP) = 1 mg/dL (10 mg/L)

6. Subject is willing to participate in the study and willing to sign the informed
consent

Open label study phase:

- Participants that have completed the initial short term portion (double blind) of the
study
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Double blind study phase:

1. Subjects who have at any time received treatment with BMS-188667 (Abatacept)

2. Subjects who within 30 days of the Day 1 visit have received treatment with any
investigational drug

3. Subjects with active vasculitis of a major organ system (except for subcutaneous
rheumatoid nodules)

4. Current symptoms of severe, progressive, or uncontrolled renal, hepatic,
hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral
disease. Concomitant medical conditions that in the opinion of the investigator might
place the subject at unacceptable risk for participation in this study

5. Mammogram requiring further investigation or biopsies leading to the diagnosis of a
clinically significant abnormality. Complete evaluation of lesion is required before
initiation of dosing

6. Subjects with a history of cancer within the last five years (other than non-melanoma
skin cell cancers cured by local resection)

7. Subjects who have a history of clinically significant drug or alcohol abuse, or admit
to consumption of more than 1 alcoholic drink per day

8. Subjects with evidence (as assessed by the investigator) of active or latent bacterial
or viral infections at the time of potential enrollment, including subjects with
evidence of Human Immunodeficiency Virus (HIV) infection, or hepatitis B or C
infection

9. Subjects with any serious or chronic infections such as pneumonia, pyelo-nephritis,
renal infection, chest infection with bronchiectasis, or sinusitis in the previous 3
months

10. Subjects with active tuberculosis requiring treatment within the previous 3 years

11. Subjects with any opportunistic infections such as herpes zoster or cytomegalovirus
(CMV) within the previous 2 months

12. Subjects with severe asthma defined as > 3 emergency room admissions in the last year
or > 3 treatments with oral steroids for asthma in the last year

13. A history of either angioedema or anaphylaxis that was associated with a reaction to a
drug

14. Subjects with the following laboratory values:

- Hemoglobin < 8.5 g/dL

- White blood cells < 3000/mm3

- Platelets < 100,000/mm3

- Serum creatinine > 2 times upper limit of normal

- Serum Alanine aminotransferase (ALAT) or Aspartate aminotransferase (ASAT) > 2
times upper limit of normal

- Any other lab values that in the opinion of the investigator might place the
subject at unacceptable risk for participation in this study

Open label study phase:

- Participants must continue to meet inclusion/exclusion criteria as in the short term
(double blind) phase of the protocol except subjects who have receiving other than
Abatacept

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2000
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/09/2009
Sample size
Target
Accrual to date
Final
524
Recruitment in Australia
Recruitment state(s)
SA,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - Adelaide
Recruitment hospital [2] 0 0
Local Institution - Malvern
Recruitment hospital [3] 0 0
Local Institution - Perth
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Malvern
Recruitment postcode(s) [3] 0 0
- Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Nebraska
Country [12] 0 0
United States of America
State/province [12] 0 0
New Mexico
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
Oregon
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
Argentina
State/province [17] 0 0
Burenos Aires
Country [18] 0 0
Argentina
State/province [18] 0 0
Buenos Aries
Country [19] 0 0
Belgium
State/province [19] 0 0
Antwerpen
Country [20] 0 0
Belgium
State/province [20] 0 0
Bruxelles
Country [21] 0 0
Belgium
State/province [21] 0 0
Gent
Country [22] 0 0
Belgium
State/province [22] 0 0
Leuven
Country [23] 0 0
Belgium
State/province [23] 0 0
Mons
Country [24] 0 0
Canada
State/province [24] 0 0
Alberta
Country [25] 0 0
Canada
State/province [25] 0 0
Ontario
Country [26] 0 0
Canada
State/province [26] 0 0
Quebec
Country [27] 0 0
Canada
State/province [27] 0 0
St. John
Country [28] 0 0
France
State/province [28] 0 0
Cedex
Country [29] 0 0
France
State/province [29] 0 0
Paris
Country [30] 0 0
Germany
State/province [30] 0 0
Berlin
Country [31] 0 0
Germany
State/province [31] 0 0
Freiburg
Country [32] 0 0
Germany
State/province [32] 0 0
Jena
Country [33] 0 0
Ireland
State/province [33] 0 0
Cork
Country [34] 0 0
Netherlands
State/province [34] 0 0
Nijmegen
Country [35] 0 0
South Africa
State/province [35] 0 0
Gauteng
Country [36] 0 0
South Africa
State/province [36] 0 0
Western Cape
Country [37] 0 0
United Kingdom
State/province [37] 0 0
Cambridgeshire
Country [38] 0 0
United Kingdom
State/province [38] 0 0
Greater Manchester
Country [39] 0 0
United Kingdom
State/province [39] 0 0
Kent
Country [40] 0 0
United Kingdom
State/province [40] 0 0
Yorkshire

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study was conducted to assess the safety and tolerability of Abatacept combined with
Methotrexate in participants with active rheumatoid arthritis (RA). The secondary objectives
were to assess efficacy, pharmacodynamic marker activity, and immunogenicity of Abatacept
combined with Methotrexate.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00162266
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries